QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether eribulin mesylate (E7389) has an impact on the
electrocardiogram (ECG) with focus on cardiac repolarization, as measured by QT/QTc interval
as well as through a pharmacokinetic-pharmacodynamic (PK/PD) analysis.